PFE

Pfizer Inc

PFE, USA

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

https://www.pfizer.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PFE
stock
PFE

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks ts2.tech

Read more →
PFE
stock
PFE

Pfizer Stock (PFE) Gets Cautious 2026 Call from Morgan Stanley — Here’s Why TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$29.0396

Analyst Picks

Strong Buy

7

Buy

2

Hold

15

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

14.71

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.59

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.70 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

24.02 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.25

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 56.33% of the total shares of Pfizer Inc

1.

Vanguard Group Inc

(9.3813%)

since

2025/06/30

2.

BlackRock Inc

(8.7044%)

since

2025/06/30

3.

State Street Corp

(5.2116%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(3.1431%)

since

2025/07/31

5.

Vanguard 500 Index Investor

(2.4753%)

since

2025/07/31

6.

Geode Capital Management, LLC

(2.2421%)

since

2025/06/30

7.

NORGES BANK

(1.6473%)

since

2025/06/30

8.

Wellington Management Company LLP

(1.3544%)

since

2025/06/30

9.

Massachusetts Financial Services Company

(1.3275%)

since

2025/06/30

10.

Fidelity 500 Index

(1.2676%)

since

2025/07/31

11.

Morgan Stanley - Brokerage Accounts

(1.2336%)

since

2025/06/30

12.

SPDR® S&P 500® ETF

(1.2083%)

since

2025/08/31

13.

iShares Core S&P 500 ETF

(1.2033%)

since

2025/08/31

14.

Northern Trust Corp

(1.1108%)

since

2025/06/30

15.

State Farm Mutual Automobile Ins Co

(0.9588%)

since

2025/06/30

16.

Bank of America Corp

(0.9051%)

since

2025/06/30

17.

Vanguard Value Index Inv

(0.8863%)

since

2025/07/31

18.

Charles Schwab Investment Management Inc

(0.8648%)

since

2025/06/30

19.

Fisher Asset Management, LLC

(0.8511%)

since

2025/06/30

20.

UBS Asset Mgmt Americas Inc

(0.7718%)

since

2025/06/30

21.

The Health Care Select Sector SPDR® ETF

(0.6828%)

since

2025/08/31

22.

Legal & General Group PLC

(0.6762%)

since

2025/06/30

23.

Amundi

(0.6587%)

since

2025/06/30

24.

Bank of New York Mellon Corp

(0.6326%)

since

2025/06/30

25.

Dimensional Fund Advisors, Inc.

(0.6113%)

since

2025/06/30

26.

Vanguard Institutional Index I

(0.6045%)

since

2025/07/31

27.

State St S&P 500® Indx SL Cl III

(0.5338%)

since

2025/08/31

28.

Goldman Sachs Group Inc

(0.5337%)

since

2025/06/30

29.

MFS Large Cap Value Equity

(0.5316%)

since

2025/06/30

30.

Royal Bank of Canada

(0.519%)

since

2025/06/30

31.

MFS Value A

(0.4693%)

since

2025/07/31

32.

Vanguard Equity-Income Inv

(0.4375%)

since

2025/06/30

33.

Vanguard High Dividend Yield ETF

(0.384%)

since

2025/07/31

34.

Vanguard Institutional 500 Index Trust

(0.3818%)

since

2025/07/31

35.

Blackrock Eq Idx Fund CF

(0.3778%)

since

2025/06/30

36.

Franklin Income A1

(0.3341%)

since

2025/07/31

37.

Blackrock Russ 1000 Eq Idx Composite

(0.3123%)

since

2025/06/30

38.

Russell 1000 Index Fund

(0.3083%)

since

2025/08/31

39.

Vanguard Health Care ETF

(0.3076%)

since

2025/07/31

40.

Pacer US Cash Cows 100 ETF

(0.2824%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.6

Latest Release

Date

2025-09-30

EPS Actual

0.87

EPS Estimate

0.63

EPS Difference

0.24

Surprise Percent

38.0952%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(6)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(8.3)
GARP
Strong GARP(6.5)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.